Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Emerging Role of Poly(ADP-Ribose) Polymerase Inhibitors in Cancer Treatment

1 Dec 2011

Abstract excerpt

Poly(ADP-ribose) polymerase (PARP) is a critical DNA repair enzyme involved in DNA single-strand break repair via the base excision repair pathway. PARP inhibitors have been shown to sensitize tumors to DNA-damaging agents and to also selectively kill homologous recombination repair-defective cancers, such as those arising in BRCA1 and BRCA2 mutation carriers. Recent proof-of-concept clinical studies have...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Source

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Identifiers

PMID: 21777194
DOI: 10.2174/138945011798829438

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Emerging Role of Poly(ADP-Ribose) Polymerase Inhibitors in Cancer TreatmentPMID 21777194Read ↗

Advances in PARP inhibitors for the treatment of breast cancer.Semantic proximity Read ↗

A pan‐tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitorsSemantic proximity Read ↗

PARP inhibitors: A new era of targeted therapy.Semantic proximity Read ↗

An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer TherapySemantic proximity Read ↗

PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targetingSemantic proximity Read ↗

Current Development of Clinical Inhibitors of Poly(ADP-Ribose) Polymerase in OncologySemantic proximity Read ↗

[From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].Semantic proximity Read ↗

PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast CancersSemantic proximity Read ↗

Poly (ADP-ribose) polymerase inhibitors in cancer therapySemantic proximity Read ↗

The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapySemantic proximity Read ↗

Poly (ADP-Ribose) Polymerase as a Novel Therapeutic Target in CancerSemantic proximity Read ↗

Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.